REPHA GmbH Biologische Arzneimittel

REPHA GmbH Biologische Arzneimittel focuses on clinical research in functional gastrointestinal disorders, with an emphasis on irritable bowel syndrome and its symptomatic burden.

• Diarrhoea-predominant irritable bowel syndrome (IBS-D)
• Mixed-type irritable bowel syndrome (IBS-M)
• Digestive symptom management

The sponsor’s trial activity is centred on patient populations experiencing chronic bowel habit disturbance and related intestinal discomfort.